{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T20:46:53Z","timestamp":1784062013568,"version":"3.55.0"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,4,13]],"date-time":"2007-04-13T00:00:00Z","timestamp":1176422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> High titer hepatitis B immunoglobulin (HBIG) has significantly reduced the recurrence of hepatitis B virus (HBV) infection after liver transplantation. We compared our experience with intramuscular (IM) HBIG prophylaxis to our earlier outcomes with intravenous (IV) HBIG and other regimens.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> One hundred and twenty\u2010three patients with acute or chronic hepatitis B underwent liver transplant at the Baylor Regional Transplant Center between July 1985 and July of 2005. Of these, 63 (43%) received long\u2010term low\u2010dose IM (n\u2003=\u200317) or high\u2010dose IV (n\u2003=\u200346) HBIG. All patients in IM group also received a nucleoside before and after transplant. These patients were compared with those transplanted earlier who received either no prophylaxis (n\u2003=\u200316) or HBIG on day zero and one only (n\u2003=\u200344).<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> HBV recurrence was significantly lower in patients who received long\u2010term HBIG [9\/38 (23.7%) for IV and 1\/17 (5.9%) for IM] compared with patients who received no treatment (8\/11; 72.7%) or only two doses of HBIG (32\/40; 80.0%). Two\u2010yr actuarial survivals were 89%, 88%, 54%, and 64%, respectively. Patients on long\u2010term HBIG by either parenteral route survived as well as patients transplanted for other indications. Post\u2010transplant recurrence of hepatitis B in the long\u2010term HBIG groups was usually controlled by intensifying antiviral therapy.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Long\u2010term low\u2010dose IM and high\u2010dose IV HBIG are equally efficacious with similar survival and early hepatitis recurrence rates. Graft loss is usually avoidable when recurrence is discovered early and aggressively treated. The IM route is preferable to IV administration due to its ease of administration and lower cost.<\/jats:p>","DOI":"10.1111\/j.1399-0012.2007.00678.x","type":"journal-article","created":{"date-parts":[[2007,4,30]],"date-time":"2007-04-30T16:48:41Z","timestamp":1177951721000},"page":"510-517","source":"Crossref","is-referenced-by-count":22,"title":["Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens"],"prefix":"10.1111","volume":"21","author":[{"given":"Robert D","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinath","family":"Chinnakotla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P","family":"Perrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran B","family":"Klintmalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,30]]},"reference":[{"issue":"4","key":"e_1_2_5_2_2","first-page":"136","article-title":"Disease recurrence following orthotopic liver transplantation","volume":"18","author":"Portmann B","year":"1986","journal-title":"Transplant Proc"},{"key":"e_1_2_5_3_2","first-page":"161","article-title":"Recurrent hepatitis B in liver allograft recipients: differentiation between viral hepatitis B and rejection","volume":"125","author":"Demetris AJ","year":"1986","journal-title":"Am J Pathol"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312163292503"},{"key":"e_1_2_5_5_2","first-page":"2387","article-title":"Immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts","volume":"19","author":"Lauchart W","year":"1987","journal-title":"Transplant Proc"},{"key":"e_1_2_5_6_2","first-page":"1549","article-title":"Recurrence of hepatitis B after liver transplantation: does hepatitis\u2010B\u2010immunoglobulin modify the recurrent disease?","volume":"22","author":"Mora NP","year":"1990","journal-title":"Transplant Proc"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.500010414"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-10-199705150-00012"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200009150-00018"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.21554"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199702150-00027"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.35858"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(00)01653-5"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.07.070"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2000.8310"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(90)90268-V"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199605150-00013"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1128\/AAC.41.7.1571","article-title":"Pharmacokinetics of hyperimmune anti\u2010human immunodeficiency virus immunoglobulin in persons with the acquired immunodeficiency syndrome","volume":"41","author":"Fletcher CV","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20464"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(03)00633-X"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310233"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051285"},{"key":"e_1_2_5_23_2","first-page":"19","article-title":"Posttransplantation: future therapies","volume":"20","author":"Peters MG","year":"2000","journal-title":"Semin Liver Dis"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000118904.63669.EB"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2007.00678.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2007.00678.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T23:18:01Z","timestamp":1696893481000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2007.00678.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,30]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1111\/j.1399-0012.2007.00678.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2007.00678.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,30]]}}}